Affordable Access

deepdyve-link
Publisher Website

Monitoring of tumor response to cisplatin with simultaneous fluorescence and positron emission tomography: a feasibility study.

Authors
  • Liu, Fei1
  • Cao, Xu
  • Liu, Shuangquan
  • Zhang, Bin
  • He, Wei
  • Song, Jinping
  • Dai, Zhongquan
  • Zhang, Bin
  • Luo, Jianwen
  • Li, Yinghui
  • Shan, Baoci
  • Bai, Jing
  • 1 Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China. , (China)
Type
Published Article
Journal
Journal of Biophotonics
Publisher
Wiley (John Wiley & Sons)
Publication Date
Nov 01, 2014
Volume
7
Issue
11-12
Pages
889–896
Identifiers
DOI: 10.1002/jbio.201300069
PMID: 23853154
Source
Medline
Keywords
License
Unknown

Abstract

Dual modality molecular imaging can capture concurrent molecular events and evaluate therapeutic efficacy from uniquely different perspectives based on different molecular targets. In this work, dual modality tomographic imaging, (18) F-fluorodeoxyglucose based positron emission tomography and subsurface fluorescence molecular tomography ([(18) F]FDG-PET/subsurface FMT), is proposed to monitor tumor response to cisplatin on a mouse xenograft model in vivo. One mouse was administered with cisplatin (1.0 mg/kg) by intraperitoneal injection once every day for 14 days, and another mouse was administered with saline to serve as the control. Dual modality [(18) F]FDG-PET/subsurface FMT imaging was conducted on days 0, 2, 5, 9, 15, and 22. In vivo imaging and quantitative analysis demonstrated the feasibility of [(18) F]FDG-PET/subsurface FMT imaging in tracking the changes of [(18) F]FDG tumor uptake and amount of red fluorescent protein (RFP) synthesized by tumor cells in the same mouse simultaneously. Dual modality [(18) F]FDG-PET/subsurface FMT imaging may thus provide a powerful tool for better understanding disease progress and treatment evaluation from different perspectives.

Report this publication

Statistics

Seen <100 times